• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources

Group Sites

• The Hindu
• Business Line
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Hyderabad , May 16

Dr Reddy's Laboratories Ltd has introduced a European research product Doxofylline, a second-generation xanthine bronchodilator.

In a press release here on Tuesday, the company said it has introduced this product under licence agreement from Kent Union Ltd, Hong Kong, and marketing co-operation with Netherlands-based Eurodrug Laboratories BV.

Doxofylline is being introduced under the brand name `Doxobid' and would be available in a pack of 10's in 400 mg dosage. Doxobid is meant to treat patients suffering from asthma & COPD (chronic obstructive pulmonary disease).

According to the company, Doxobid would further help it consolidate its position in the asthma & COPD segment as the company has been moving towards strengthening its respiratory portfolio.

More Stories on : Announcements | New Products & Services | Health | Dr. Reddy's Laboratories Ltd | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
`Make public report on Bombay High fire'

Copyright © 2006, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line